{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.187","upperLimit":"0.311","value":"0.245"},{"groupId":"OG001","lowerLimit":"0.289","upperLimit":"0.425","value":"0.355"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"description":"Overall response rate is defined as number of patients with complete response (CR) or partial response (PR) divided by all patients. Responses are evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) guideline. CR is defined as disappearance of all target and non-target lesions. PR is defined as disappearance of target lesions or at least a 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameters), and persistence of one or more non-target lesion(s).","dispersionType":"95% Confidence Interval","groups":[{"description":"ARM A: Patients receive one of the four chemotherapy regimens\n\nARM IA: Patients receive chemotherapy comprising docetaxel intravenously (IV) over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nARM IIA: Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nARM IIIA: Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nARM IVA: Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Chemotherapy Arm (Arm A)"},{"description":"ARM B: Patients receive bevacizumab in addition to the chemotherapy regimen as in arm A\n\nARM IB: Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA.\n\nARM IIB: Patients receive bevacizumab as in arm IB and docetaxel and carboplatin as in Arm IIA.\n\nRegimen 2:\n\nARM IIIB: Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA.\n\nRegimen 2 carbo:\n\nARM IVB: Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA.","id":"OG001","title":"Chemotherapy+Bevacizumab (Arm B)"}],"paramType":"NUMBER","populationDescription":"All randomized patients","reportingStatus":"POSTED","timeFrame":"on both arms, assessed every 2 cycles during chemotherapy treatment, then assessed every 9 weeks until progression up to 5 years from study entry; patients on arm B were assessed every 2 cycles for additional 12 weeks before changing to every 9 weeks","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"proportion of participants"}